Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two major forms of leukemia developed from myeloid cells (MCs). To understand why AML and CML occur in children, we analyzed the causes and the mechanism of cell transformation of a MC.
This paper has the following structure: 
I. Introduction

II. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML
Introduction
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two major forms of leukemia arising from myeloid cells (MCs) in marrow. "MCs" include all the cells of myeloid linage at any developing stages. AML and CML occur mostly in adults but also in children. Myelodysplastic syndrome (MDS) is a type of pre-leukemia that occurs mainly in old people. In updated WHO classification of AML and MDS in 2016, some subtypes of AML are renamed by their specific DNA changes, for example, "AML with t(6;9)" and "AML with t(8;21)" (Arber, 2016) . The novel classification of AML is important in clinic for making a more precise diagnosis and prognosis of an AML. Nevertheless, in this paper, we discuss AML by using the FAB classification of AML subtypes (M0-M7). The classic name of an AML subtype gives information of the pathology and the cell of origin of an AML. On the causing factors for leukemia, we have recently proposed a hypothesis: repeated boneremodeling during bone-growth may be a source of cell injuries of the hematopoietic cells (HCs) in marrow (Wang-Michelitsch, 2018a). HCs include hematopoietic stem cells (HSCs), MCs, and the lymphoid cells (LCs) in marrow. We discuss in this paper the developing mechanisms of AML and CML by this hypothesis. Our discussion is driven by the following questions:
We aim to show by our discussion that: pediatric AML and CML may develop as a result of cell transformation of a MC via accelerated pathway; and the repeated bone-remodeling
What is the cause for cell injuries of myeloid cells (MCs) in marrow?
Why can a MC be transformed more rapidly than a tissue cell?
Is it possible that repeated bone-remodeling is a source of cell injuries of MCs?
Why do AML and CML occur in children? 
II. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) affect both adults and children
AML and CML affect both adults and children, but MDS affects mainly the people older than age 60 ( Figure 1 ). AML can occur in infants, and has a small peak before age 2. 10% of CML patients are children and adolescents; however CML occurs rarely in children under age 4. Pediatric AMLs can be different from adult cases by disease presentation, pathology, and prognosis. Leukemia patients at different ages need to be given different treatments, thus they are regrouped often by age: infants (age 0-2), children (age 3-14), adolescents (age [15] [16] [17] [18] [19] , young adults (age 20-39), and adults (age > 39). Pediatric patients are the patients that are younger than age 15 (Kent, 2009 ). AML and MDS have much higher incidences than CML. In USA, the incidences of AML, CML and MDS in 2013 are respectively 12950, 5980, and 14100. All these three forms of leukemia have higher incidences in males than in females. AML (blue line) and CML (green line) occur mostly in adults but also in children. AML can occur in infants, and has a small peak before age 2. CML occurs rarely before age 4. MDS occurs mainly in old people (black line). AML and MDS have much higher incidences than CML.
AML occurs at all ages but mostly in adults
AML is a form of blood cancer that exhibits as abnormal cloning and differentiation of myeloid blast cells in marrow. AMLs account for 80% of adult leukemia cases and 15% of pediatric cases. AML has increasing incidence with age ( Figure 1 ). However, AML has a small peak before age 2 (Pérez-Saldivar, 2011 
Different subtypes of AML occur at different ages
By pathology, AML is classified into M0-M7 eight subtypes. Diagnosis of a subtype of AML is based on the characteristics of leukemic cells on morphology, immunophenotype, and cytogentic changes (Saultz, 2016) . The names of AML subtypes are listed here: M0: Undifferentiated acute myeloblastic leukemia; M1: Acute myeloblastic leukemia with minimal maturation; M2: Acute myeloblastic leukemia with maturation; M3: Acute promyelocytic leukemia (APL); M4: Acute myelomonocytic leukemia; M4eos: Acute myelomonocytic leukemia with eosinophilia; M5: Acute monocytic leukemia; M6: Acute erythroid leukemia; and M7: Acute megakaryoblastic leukemia. Different subtypes of AML have different incidence rates in population and have different age-distributions. M0, M1 and M2 are all myeloblastic leukemia and together represent 45% of AMLs. The incidence rates of M3, M4/M4eos, and M5 are respectively 10%, 25%, and 10%. M6 and M7 are rare (Santos, 2009; Masetti, 2015) .
M0 occurs mostly in infants and older adults (Venditti, 1997). M1 and M2 are the most common subtypes of AML in children and adults, but they are rare in infants (Table 1) . M3 occurs mostly at age 35-40. 50% of IAMLs are M4 and M5, and 20% are M7 (Masetti, 2015) . M6 occurs mostly in people older than age 60 (Santos, 2009) . M7 is the most common subtype of AML in Down's children. A child with Down syndrome may have 16-fold higher risk than other children on developing AML. Familiar AMLs occur mostly before age 3. In general, pediatric AMLs have better prognosis than adult cases after treatment. However, most IAMLs are chemotherapy-resistant. The 5-year overall survival rates (OS) in infants, children, and adults (age >15) are respectively 10%-30%, 50%, and 30%-40% (Master, 2016) . Among all subtypes of AML, APL (M3) has the best prognosis (Kansal, 2016 ).
Different subtypes of AML have different forms of recurrent DNA changes
More than 300 forms of chromosome changes (CCs) and molecular mutations have been identified in AML cells. CCs have higher occurrences in pediatric AMLs: in 70%-85% of pediatric AMLs whereas in 50% of adult cases (Kumar, 2011) . Different subtypes of AML often have different recurrent forms of CCs in tumor cells (Kansal, 2016 
CML occurs in both children and adults
CML is an indolent form of blood cancer and it exhibits as over-production of all types of blood cells in myeloid lineage (Sarwar, 2015) . CML occurs in both children and adults ( Figure 1 ). 10% of CML patients are children and adolescents (Höglund, 2015) . However, CML occurs rarely in young children (< age 4) (Homans, 1984 However, Ph translocation is not specific for CML. Ph translocation is also found in 10%-20% of cases of acute lymphoblastic leukemia (ALL). In these ALLs, Ph translocation contributes to the cell transformation of lymphoblast. Ph translocation is the main form of CC in CML at chronic phase. However, secondary DNA changes can be generated during the progression of CML. Some of the secondary DNA changes may lead to blast crisis of CML. These secondary DNA changes include t(8;21), second Ph translocation, isochromosome 17q, and (+19) (Bozkurt, 2013 ).
CML is a form of myeloid proliferative neoplasm (MPN)
CML is a proliferative disease, as a type of MPN. Other types of MPN include polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), and chronic neutrophilic leukemia (CNL) (Clara, 2016 (Pellagatti, 2015) . Apart from del(5q), frequent forms of CCs in MDS include del(7q), del(20q), (-5) , -Y, (+8), and (-7) (Haase, 2008) . Some forms of CCs, including (+8), complex karyotype, and abn (7), are associated with poor prognosis of MDS.
Juvenile myelomonocytic leukemia (JMML) is a type of MDS/MPN
JMML is an aggressive form of hematopoietic disorder in infancy characterized by excessive production of monocytes and granulocytes (Toren, 1991; Sethi, 2013 .
III. Development of myeloid cells (MCs) in bone marrow
AML and CML are both a leukemia resulting from cell transformation of a MC. To understand how a MC is transformed, we firstly make a brief review on the developing process of MCs and the characteristics of MCs. In humans, after birth, all of our blood cells including MCs and lymphoid cells (LCs) are produced by the HSCs in marrow through hematopoiesis. Hematopoiesis has in general four steps: A. a HSC produces a progenitor cell; B. a progenitor cell then proliferates rapidly to produce a large number of blast cells in different lineages; C. a blast cell then proliferates and differentiates into different types of pro-cytes (immature cells); and D. a pro-cyte then divides for several times to develop into mature cells ( Figure 2 ). In the present paper, "hematopoietic cell" (HC) is the general name for all the blood forming cells in marrow, including HSCs, MCs, and LCs. Among all the nucleated non-erythroid HCs in marrow, 0.001% are HSCs, 2%-4% are blast cells, 20%-30% are pro-cytes, and more than 60% are mature cells.
Figure 2. Development of myeloid cells in marrow
HSCs are the stem cells for all types of blood cells. For hematopoiesis, a HSC needs to produce a progenitor cell: myeloid progenitor cell (MPC) or lymphoid progenitor cell (LPC). A MPC differentiates firstly into three types of progenitor cells: megakaryocyte-erythrocyte progenitor (MEP), granulocyte-monocyte progenitor (GMP), and mast-cell progenitor. A MEP will differentiate into two types of blast cells: megakaryoblasts and erythroblasts, which will differentiate further respectively into pro-megakaryocytes and pro-erythocytes. A GMP will differentiate into two types of blast cells: monoblasts and myeloblasts. A myeloblast will differentiate further into three types of pro-myelocytes: neutrophilic, basophilic, and eosinophilic, respectively. A monoblast will differentiate uniquely into pro-monocytes. Pro-cytes are also proliferative but uni-potent. Each pro-cyte will differentiate into a number of mature cells of the same type. 
Ancestors of MCs: hematopoietic stem cells (HSCs)
HSCs are the ancestors for all HCs and all blood cells. HSCs are regenerable for our whole lifetime. Through symmetrical cell division, a HSC renews itself by producing two daughter HSCs. By asymmetrical cell division, a HSC produces two different cells: a new HSC and a It is reported that clonal hematopoiesis occurs in 20% of people older than age 90 (Shlush, 2015) . Some MDSs may develop from clonal hematopoiesis.
Developing MCs: including progenitor cells, myeloblasts, and pro-cytes
Progenitor cells, myeloblasts, and pro-cytes are precursors of mature MCs. Progenitor cells and blast cells are oligo-potent, whereas pro-cytes are uni-potent (Arai, 2016) . A progenitor cell proliferates and differentiates into different types of blast cells, and a blast cell will proliferate and differentiate into one or more types of pro-cytes. For example, a MPC can firstly differentiate into three types of progenitor cells (also blast cells): megakaryocyteerythrocyte progenitor (MEP), granulocyte-monocyte progenitor (GMP), and mast-cell progenitor. A MEP will differentiate into two types of blast cells: megakaryoblasts and erythroblasts, which will differentiate further respectively into pro-megakaryocytes and proerythocytes. A GMP will differentiate into two types of blast cells: monoblasts and myeloblasts. A myeloblast will differentiate further into three types of pro-myelocytes: neutrophilic, basophilic, and eosinophilic, respectively ( Figure 2 ). Differently, a monoblast will differentiate uniquely into pro-monocytes. Pro-cytes are also proliferative but uni-potent. Each pro-cyte will differentiate into a number of mature cells of the same type. In myeloid lineage, a pro-cyte develops into mature cells via three stages of differentiation: pro-cyte, cyte, and meta-cyte. For example, maturation of neutrophilic granulocytes needs to pass three developing stages: pro-myelocyte, myelocyte and mega-myelocyte.
Progenitor cells, blast cells, and pro-cytes are all developing HCs, which are proliferative and immature on cell functions. Blast cells account for 2%-4% of nucleated HCs in marrow. The number of pro-cytes should be much higher than that of blast cells, because a blast cell needs to divide at least one time to develop into pro-cytes. Thus, pro-cytes may represent the largest part of developing HCs in marrow. Although not fully developed, pro-cytes are more mature on cell functions than blast cells. Being large in number and proliferating constantly, developing HCs may have high risk to be injured during DNA synthesis and cell division by damaging factors. In another word, developing HCs have higher risk of DNA injuries and DNA changes than mature cells.
Mature MCs: including granulocytes, monocytes, red cells, and megakaryocytes
A pro-cyte will divide for several times to develop into mature cells. Except T cells, all types of blood cells are fully developed in marrow. Mature MCs have several sub-lineages, including granulocytes (neutrophils, basophils, and eosinophils), monocytes, erythrocytes (red cells), and megakaryocytes (platelets) (Figure 2 ). Being mature on cell functions and nonproliferative, a mature MC may have lower risk of DNA injuries and DNA changes than a developing MC. Monocytes and granulocytes are the main cells for innate immunity. Monocytes can derive into macrophages, osteoclasts, and dendritic cells. The functions of monocytes are phagocytosis, cytokine production, and antigen-presentation. A monocyte is a large cell with big smooth nucleus and large cytoplasm. This indicates that a monocyte produces a large number of intracellular proteins. A granulocyte is a middle-sized cell, but much bigger than a naïve lymphocyte by its large cytoplasm. A granulocyte produces a great deal of granule proteins in cytoplasm. These proteins are important for the function of a neutrophil: swallowing and digesting bacteria and fungi in cytoplasm.
IV. A potential source of cell injuries of hematopoietic cells (HCs) in marrow: the repeated bone-remodeling during bone-growth and bone-repair
DNA changes are the driver for cell transformation and for cancer development. However, DNA changes are generated in a cell as consequences of cell injuries and DNA injuries. So far, the main cause for cell injuries of MCs associated with leukemia development is unknown. Some environmental factors such as exposures to radiation or toxic chemicals may be related to leukemia development. However, the high incidence of AML in young children cannot be explained completely by environmental factors. After analyzing the occurring age of ALLs, we have hypothesized that repeated bone-remodeling during bone-growth may be a source of cell injuries of HCs and a trigger for ALL development in children (Wang-Michelitsch, 2018a).
ALL occurs mostly at age 0-20 when the bones are growing. The incidence of ALL after age 25 is very low. This phenomenon suggests that bone-growth may be related to ALL development. In humans, hematopoiesis takes place mainly in marrow cavities and the spongy part of bones. Marrow cavity and spongy bone are developed and enlarged with the growth of a bone. Bone-growth is a result of repeated modeling-remodeling of bone tissues (Rockville, 2004) . Bone-remodeling is a process of digestion of the bone tissues exposed to marrow cavity by osteoclasts. Osteoclasts digest bone-matrix by secreting acid substances and proteinases. It is quite possible that these digestive substances and the bone debris produced during bone-remodeling injure occasionally the HCs in marrow cavity. Naturally, the risk of a HC to be injured by bone-remodeling is quite low. However, long-term (25 years) repetition of bone modeling-remodeling for bone-growth can highly increase this risk.
In addition, young children have high incidence of bone fractures because of their fragilities on muscles and bones. Bone injuries may disturb bone-growth and increase the frequency of bone-remodeling. Thus, in a child, bone injuries (external) increase the risk of cell injuries of HCs by bone-remodeling during bone-growth (internal). In fact, bone-remodeling occurs also during bone-repair and bone adaptation. Thus HCs can be affected by bone-remodeling at all ages. Bone-remodeling may be a causing factor not only for pediatric leukemia but also for adult leukemia.
Cell injuries by internal damage may occur also to other cells including tissues during body development and during inflammations. DNA changes can be also generated in some injured tissue cells. However, for a tissue cell, cell transformation needs a long time as a co-effect of external and internal factors. Differently, a MC can be transformed more rapidly than a tissue cell as that seen in AML and CML. Thus, the effect of internal damage on a MC can be recognized. We will discuss in next parts why a MC can be transformed more rapidly than a tissue cell.
V. Generation and accumulation of DNA changes in HCs is a result of repeated cell injuries and repeated cell proliferation
There are two major types of DNA changes: point DNA mutation (PDM) and chromosome change (CC). PDM appears as alteration, deletion, or insertion of one or two bases in a DNA. PDM is called also gene mutation and molecular mutation. CC is called also cytogenetic change and abnormal karyotype. A CC can be a numerical CC (NCC) or a structural CC (SCC). A NCC exhibits as loss or gain of one or more chromosomes. For example, (-7), (+7), hyperdiploid, and aneuploid are all forms of NCCs. A SCC exhibits as rearrangement of part of a chromosome, such as translocation (t), deletion (del), gain (+), inversion (inv), and amplification (amp) of part of a chromosome.
Different types of DNA changes are generated in a cell by different mechanisms. Studies show that a PDM is generated as a result of Misrepair of DNA on a double-strand DNA break (DSB) (Rothkamm, 2002; Natarajan, 1993; Bishay, 2001) . Similarly, generation of SCC is also a result of Misrepair of DNA. A SCC can be generated when a cell has multiple DSBs (Wang-Michelitsch, 2018a). Differently, generation of NCC is rather a consequence of dysfunction of cell division promoted by damage. In our view, a PDM/SCC is made for repair of DNA for preventing cell death, thus it is not really a mistake. Differently, a NCC is not generated for "repair"; thus survival of a cell with a NCC is a real mistake. Unfortunately, a NCC can affect multiple genes and cause cell transformation rapidly.
Normally, a somatic cell has quite low opportunity to survive from a DSB 
VI. Different types of DNA changes have different effects on a cell
DNA changes are the driver for cell transformation; however, not all the DNA changes contribute to cell transformation. Big CCs may cause cell death, but silent PDMs have no effect on a cell. CCs are rare in cancers developed from tissue cells, but not rare in leukemia and lymphoma. This phenomenon indicates that a tissue cell can be transformed mainly by PDMs (gene mutations), but a blood cell and a HC can be transformed not only by PDMs but also possibly by CCs.
Effect of a point DNA mutation (PDM) on a cell
A PDM can affect at most "one" gene. Since most regions of a DNA (in one chromosome) are non-coding for proteins, most PDMs are silent in a cell. However, if a PDM occurs in the coding region of a gene and affects expression of the gene, the PDM is not silent. There may be two situations: A. if the gene is essential for cell survival and it is expressed constitutively, production of non-functional proteins or failure/reduction of gene expression can make the cell die; and B. if the gene is expressed only when there is an inducer, failure of gene expression does not necessarily cause cell death. In situation A, the PDM is fatal, but in situation B, the PDM is mild. Hence, most PDMs are silent or mild, by which they can "survive" and accumulate in cells. By accumulation, some mild PDMs may exhibit their "emergent effects" on a cell. If some of the PDMs make a cell able to proliferate independently, the cell is transformed. It is possible that some forms of PDMs do not affect directly cell functions but they may alter genome stability and accelerate generation of other DNA changes. These PDMs also contribute to cell transformation.
Three types of chromosome changes (CCs) by their effects on a cell
In AML, CCs can be found in 80% of pediatric cases but only 45% of adult cases. This phenomenon suggests that the rapider cell transformation of a MC in pediatric AML is related to CCs. In general, a CC has greater effect than a PDM on a cell, but different forms of CCs may have different effects. Thus it is essential to regroup CCs by their impacts on a cell. We classify CCs into three groups by their effects on a MC: great-effect CCs (GECCs), mildeffect CCs (MECCs), and intermediate-effect CCs (IECCs) (Box 1).
Great-effect CCs (GECCs)
GECC is a type of CC that affects one or more genes and can alone drive cell transformation in "one step" (Box 1). For most types of cells, a GECC will cause cell death. However, for certain types of cells, a GECC may be not fatal, but rather be sufficient for driving cell transformation directly (Wang-Michelitsch, 2018b). The aneuploid in pediatric ALL and the t(8;14) in Burkitt lymphoma (BL) are two examples of GECCs. ALL and BL have both a peak incidence in children, indicating that a lymphoblast and a centroblast have a risk to be transformed by a GECC. Differently, AML and CML do not have a peak incidence in children and other ages. This suggests that a MC cannot be transformed in "one-step" by a GECC. In another word, a MC cannot survive from a GECC. 
Intermediate-effect CCs (IECCs)
IECC is a type of CC that affects one or more genes and contributes to cell transformation (Box 1). An IECC cannot alone cause cell death or cell transformation. A mature MC and a HSC may have low tolerance to an IECC. Thus, an IECC is generated more often in a developing MC, such as progenitor cell, blast cell, and pro-cyte. A cell may have increased risk of generation of IECC, when it has already other DNA changes. Some PDMs/MECCs may affect the chromosome stability in a cell and increase the sensitivity of a DNA to damage. Namely, the more PDMs/MECCs a cell has, the more risk has the cell on generation of IECC. Thus, IECCs have increasing occurrence in MCs with age of our body. IECCs may also accumulate in MCs, but this opportunity is low.
The cell transformation driven by an IECC is a co-effect of the IECC and other PDMs/MECCs. One reason is that: generation of IECC is often related to early PDMs/MECCs in the cell. With stronger effect than a PDM/MECC, an IECC can accelerate cell transformation. An IECC drives cell transformation possibly by affecting an oncogene or a tumor suppressing gene. A good example of IECC is the Ph translocation (t(9;22)) in CML. Ph translocation contributes to the cell transformation of MC in CML by generating fusion gene of BCR-ABL1 and activating permanently ABL1 tyrosine kinase. CML occurs rarely in young children, but it has increasing incidence with age (Kang, 2016) . This phenomenon suggests that Ph translocation has increasing occurrence in MCs with age of an individual. IECCs might represent the cytogenetic abnormalities that are associated with intermediateand high-risk prognosis of AML. These CCs include t(9; 11), (+8), (-y), t(6;9), t(9;22), (-5), (-7), inv (3), and abn(3q). An IECC is a driver DNA change, thus it can be chosen to be a blocking target in targeted cancer treatment.
VII. A MC may have higher survivability from DNA changes than a tissue cell
Different forms of DNA changes have different effects on a cell; however, the same form of DNA change may have different effects on different types of cells. MCs at different developing stages may have also different tolerances to a DNA change. In this and next parts, we discuss why a MC can be transformed more rapidly than a tissue cell. In our view, two factors make it possible that MC is transformed more rapidly. These two factors are: A. a MC may have higher tolerance to DNA changes than a tissue cell; and B. A MC may require obtaining fewer cancerous properties for transformation than a tissue cell.
Higher tolerance of a MC to DNA changes than a tissue cell
A blood cell is different from a tissue cell by surviving environment. Here, "blood cells" include all the mature blood cells and all the hematopoietic cells in bloodstream and in marrow. A tissue cell is anchor-dependent for survival, but a blood cell is anchor-independent. If a tissue cell fails to anchor to its neighbor cells or extracellular matrixes (ECMs), the cell will die through apoptosis (cell suicide). For a tissue cell, cell adhesion molecules are essential for cell survival. Major types of adhesion molecules include cadherins, selectins, and integrins (Li, 2012) . If a DNA change affects production of one of these molecules in a tissue cell, the cell may die. A blood cell expresses also adhesion molecules. However, for a blood cell, the adhesion molecules are used for cell development and cell functions, but not used for anchoring to other cells/ECMs for survival. For example, a mature granulocyte can survive no matter whether it is in bone marrow, bloodstream, or tissue. Thus, cell adhesion molecules of a granulocyte are not essential for cell survival. Failure of expression of these molecules by DNA changes does not necessarily cause death of a granulocyte.
In addition, at different developing stages, MCs express different CD molecules. For example, CD33 and CD34 are only expressed on developing MCs but not on mature MCs (Dutta, 2014) . In contrast, molecules including CD17 and CD93 are only expressed on mature MCs. MPCs (myeloid progenitor cells) express CD34, CD33, and CD38, but GMPs express CD33, CD34, and CD31. Myeloblasts produce CD13, CD15, and CD33, whereas mature neutrophils produce CD17, CD32, CD35, CD43, and CD93. These molecules are not expressed permanently but rather by inducers in environment. Inducible expression of CD molecules implies that a MC can survive no matter these molecules are expressed or not. If a mutation occurs to the gene of one of these molecules, the mutation may not affect the cell. Taken together, due to the anchor-independence for survival and the inducible expression of cell surface molecules, a MC and other blood cells may have higher survivability from DNA changes than a tissue cell. Namely, a DNA change that is fatal for a tissue cell may not be necessarily fatal for a MC.
A developing MC may have higher survivability from DNA changes than a mature MC
A developing MC such as progenitor cell, myeloblast, and pro-cyte is immature on cell functions, thus it may be more tolerant to DNA changes than a mature MC. Having high integrity on cell functions, a mature cell is alert to any tiny change occurred to the cell. However, because of immaturity on some cell functions, an immature MC may be unable to "sense" a change in the cell. In addition, to have full cellular functionality, a mature cell needs to express more types of molecules than an immature one. Thus, more genes should be activated in a mature cell. A DNA change that occurs to a gene that is activated only in mature cells can only affect a mature cell but not a developing cell. Namely, a DNA change that is fatal for a mature MC may be not fatal for an immature MC. Therefore, a developing MC may have higher tolerance to DNA changes than a mature cell. The high survivability from DNA changes makes a developing MC have a risk to be transformed by a CC (chromosome change).
However, a developing MC may have lower tolerance to DNA changes than a developing lymphoid cell (LC), such as lymphoblast and pro-lymphocyte. It is known that naïve lymphocyte is the smallest cell in our body. A naïve lymphocyte has little cytoplasm, indicating that it does not produce many intracellular proteins. This means that most genes may be switched-off in a naïve lymphocyte and its precursor LCs. Differently, a mature MC such as monocyte and granulocyte has a large cytoplasm. This indicates that a monocyte/granulocyte produces a great deal of intracellular proteins. It is probable that many genes that are not activated in a LC are activated in a MC. Thus, a DNA change that has an effect on a MC may have no effect on a LC. Namely, a LC may be tolerant to more types and more number of DNA changes than a MC. Taken together, with respect to the tolerance to DNA changes, developing LC > developing MC > mature MC > tissue cell.
VIII. A MC may require obtaining fewer cancerous properties for transformation than a tissue cell
A tumor can grow rapidly and even invade into other organs due to some cancerous properties of the tumor cells (Cooper, 2000) . Among all cancerous properties, the most important five are: stimulator-independent mitosis (SIM), loss of cell-contact inhibition (LCCI), production of matrix metalloproteinase (PMM), anoikis-resistance (AR), and acquired mobility (AM) ( Table 2 ). SIM and LCCI are two essential properties for a non-malignant tumor cell. SIM gives a cell the ability of stimulator-independent proliferation. LCCI enables an unlimited cell proliferation by overcoming the cell-contact inhibition in a tissue. PMM, AR, and AM are essential properties for a malignant tumor cell. These three properties make a tumor cell invasive and metastatic. For a tissue cell, SIM and LCCI are the first two properties to acquire for cell transformation. Thus, transformation of a tissue cell often begins by non-malignant transformation. When a tumor cell acquires additionally one of PMM, AR, and AM, it undergoes malignant transformation (Wang-Michelitsch, 2018b).
Interestingly, a blood cell and a HC are born with some properties similar to that of a cancer cell. Firstly, a blood cell is anoikis-resistant, thus it is AR-positive. Secondly, cell proliferation of HCs in marrow is not restricted by cell-contact inhibition; hence HCs are LCCI-positive. Thirdly, a blood cell has auto-mobility for migration in bloodstream, lymph, and tissues, thus it is AM-positive. Finally, a blood cell can produce matrix metalloproteinases during migration, thus it is PMM-positive. Taken together, a blood cell/HC is born with four properties that are needed for cell transformation, and these properties are LCCL, PMM, AR, and AM (Table 2) . Hence, a blood cell/HC needs to obtain only "one" property: namely the SIM, for transformation. This means that a blood cell/HC can be transformed by fewer number of DNA changes than a tissue cell, thus it can be transformed more rapidly. As a result of repetition of cell injuries, the incidence of cell transformation via this pathway increases with age. Thus, cell transformation via slow pathway takes place mainly at old age. A leukemia that results from cell transformation via slow pathway occurs mainly in adults and rarely in children. Thus, MDS may develop mainly via this pathway (Figure 4 ). Some adult subtypes of AML, such as M6, may develop via this pathway. CML occurs at any age; hence it may not develop via this pathway. Transformations via different pathways occur at different ages. A cell transformation via slow pathway occurs mainly in adults and has increasing incidence with age. A cell transformation via accelerated pathway can occur at any age and has also increasing incidence with age.
Accelerated pathway: by accumulation of PDMs, MECCs, and IECC(s) through a few generations of cells
A MC can obtain SIM also by accumulation of PDMs, MECCs, and IECC(s). Some forms of CCs in AML, such as t(9; 11), (+8), (-y), t(6;9), t(9;22), (-5), (-7), inv (3), and abn(3q), may be IECCs. With stronger effect than a PDM/MECC, an IECC can accelerate cell transformation driven by accumulation of PDMs/MECCs. Thus, a cell transformation driven by IECC(s) and PDMs/MECCs is rapider than that driven only by PDMs/MECCs in slow pathway. We refer the IECC-driven pathway as to an "accelerated pathway" (Figure 3) . A transformation via accelerated pathway needs to be achieved also through some generations of cells, but fewer than that in slow pathway. An IECC can be generated in a cell at any time; however it may have increasing occurrence in MCs with age of our body. Therefore, a cell transformation via accelerated pathway can occur at any age, but it has increasing incidence with age. A leukemia that develops via this pathway occurs in both adults and children, but more in adults. Thus, CML develops more likely via this pathway, and Ph translocation is the IECC in CML (Figure 4) . Pediatric AMLs and some adult AMLs, such as M1, M2, M3, M4, and M5, may develop via this pathway. In these two pathways, the final PDM/MECC/IECC is generated in the first transformed cell, but other PDMs/MECCs/IECC(s) are generated in precursor HSCs/MCs. Transformations via different pathways occur at different ages. Thus, the age of occurrence of leukemia is determined by the transforming pathway of a MC. A leukemia that occurs mainly in adults, such as MDS and adult AML, is often a result of cell transformation via slow pathway. A leukemia that occurs in both children and adults, such as CML and pediatric AML, is more likely a result of cell transformation via accelerated pathway.
Similar to that in slow pathway, most of the driver PDMs/MECCs in a cell transformation via accelerated pathway are generated in the precursor HSCs/MCs of the first transformed cell. Thus, cell injuries of HSCs in marrow may contribute to developments of all forms of myeloid leukemia, including AML, CML, and MDS. Since HSCs have low tolerance to an IECC, the IECC associated with development of AML/CML may be more often generated in the first transformed MC or one of its precursor MCs.
Leukemia is a fatal disease, because accumulation of leukemia cells in marrow cavity can cause failure of hematopoiesis. Failure of cell differentiation of leukemia cells is the main reason for the accumulation of leukemia cells in marrow cavity. Thus, the severity of leukemia is determined mainly by the degree of cell differentiation of leukemia cells. If the cell differentiation is normal, leukemia cells can develop into mature cells, which can enter bloodstream and do not accumulate in marrow. However, if the cell differentiation is abnormal, leukemia cells cannot develop into mature cells and have to accumulate in marrow.
Thus, the cell transformations of a MC in different forms of leukemia may be different by "grades". Transformation of a cell can be differentiation-affected or differentiation-nonaffected. If cell differentiation is not at all affected, the transformation is at low-grade. If cell differentiation is severely affected, the transformation is at high-grade. Our analysis shows that pediatric AML/CML may be a result of transformation of a MC via accelerated pathway. In this part, we will interpret the developing characters of AML, CML, and MDS by our hypothesis. Firstly, although these three forms of leukemia are different by occurring age, pathology, and prognosis, they may have common causes. They may be all related to the cell injuries of HSCs and MCs caused by external and/or internal damaging factors. For adult cases, repeated exposures to radiation/chemicals and repeated boneremodeling during bone-growth and bone-repair may be all related to leukemia development. However, for pediatric cases, repeated bone-remodeling during bone-growth may be a more important causing factor. On all three forms of myeloid leukemia, men have higher incidences than women. One reason may be that: men have higher risk of bone injuries by their heavier body weight and heavier physical work.
AML: as a result of high-grade transformation of a developing MC via slow or accelerated pathway
AML can occur at any age and has increasing incidence with age. Thus, AML may develop as a result of cell transformation of a MC via slow or accelerated pathway. AML has two times of incidence as CML. The higher incidence of AML than CML may be due to two factors: A. AML can develop from all types of developing MCs, but CML arises only from a MPC; and B. AML can develop via both slow and accelerated pathways, but CML develops mainly via accelerated pathway. Pediatric AML develops more likely via accelerated pathway, whereas adult AML may develop via slow or accelerated pathway (Table 4) . Among all the CCs in AMLs, some forms including t(6; 9), (-5), inv (3), t(9;22), and abn(3q) may be IECCs, because they are associated with a poor prognosis of AML. The AMLs that have these IECCs may develop via accelerated pathway. Other forms including t(15; 17), t(8; 21), inv(16), t (11;17) , and t(9;11) may be MECCs, because they are related to a good prognosis of AML.
The severity of an AML is determined by two factors: the maturity of the cell-of-origin and the grade of cell transformation. For a developing MC, high-grade transformation will lead to failure of cell differentiation and production of immature leukemia cells; low-grade transformation will lead to over-production of mature cells CML is a proliferative disease, suggesting that it is a result of low-grade transformation of a MPC (Table 3 ). The progression of CML from chronic phase to blast crisis may be a result of cell transformation of a MPC from low-grade to high-grade. The CCs observed in CML, including t(8;21), second Ph translocation, iso(17q), and (+19), may be secondary DNA changes. However, some of them may drive further transformation of CML cells. Ph translocation may be related to the generation of some of the secondary DNA changes. As a form of CC, Ph translocation may affect the genomic stability in a cell and make a CML cell more fragile to DNA damage (Neviani, 2014 (-5) , and (-7), they may be mostly secondary DNA changes.
MDS and secondary AML are often treatment-resistant. Two factors may be associated with the treatment-resistance of an adult cancer (leukemia): the heterogeneity of cancer cells and the existence of pre-cancer cells. Firstly, cancer heterogeneity is a result of generations of secondary DNA changes in cancer cells. During the slow progression of an adult cancer, different secondary DNA changes may be generated in different cells. Thus, different cancer cells will have different sensitivities to a treatment. Secondly, in an adult cancer, the "sister cell" and some of "cousin cells" of the first transformed cell are s kind of "pre-cancer cells". These cells have most of the DNA changes that the transformed cell has, because they all have the same precursor HSCs and MCs. A pre-cancer cell can be promoted to transform by chemotherapy or radiotherapy (Rothkamm 2002 ). Thus, existence of pre-cancer cells may be a reason for the relapse of an adult cancer (leukemia). In targeted treatment, the selected target DNA changes should be those that are generated earlier, because these DNA changes may exist in all tumor cells. However, further progression of a cancer may anyway alter the sensitivities of cancer cells to a treatment. Targeted treatment may be beneficial for some patients, but its effect is limited.
Infant AML and JMML: are they consequences of defective development of MCs?
AML has a small peak incidence before age 2. In our view, only a cell transformation via rapid pathway can have a peak incidence at certain age (Wang-Michelitsch, 2018b). Thus, we hypothesize that some Infant AMLs (IAMLs) may develop by rapid cell transformation of an abnormal-developed MC by a great-effect CC (GECC). In our recent discussions on lymphoid leukemia, we have proposed that a developing lymphoid cell such as lymphoblast may have a risk to be transformed by a GECC. We found out that, by the hypothesis of a rapid pathway of transformation of a lymphoblast, we can understand the big peak incidence of ALL in children (Wang-Michelitsch, 2018b). However, a normal developing MC may be not tolerant to a GECC and unable to be transformed via rapid pathway. In addition, ALL peaks at age 2-5, but IAML peaks at age 0-2. The peak of IAML is much smaller than that of ALL. These differences between ALL and IAML indicate that IAML may have a distinct causing factor from pediatric ALL.
It is known that IAML children have often hereditary conditions, including Down syndrome, Fanconi anemia, Diamond-Blackfan syndrome, and Li-Fraumeni syndrome (Saida, 2017) . A child with Down syndrome has 16-fold risk higher than other children on IAML development. It is possible that infants of these syndromes have deficiencies on functions of HSCs/MCs due to congenital genetic abnormalities. A genetic abnormality may have two effects on a MC: defective cell differentiation and reduced genome stability. On one hand, the defective cell differentiation can make a MC have increased tolerance to DNA changes. On the other hand, forms of CCs such as t (1;22) and MLL rearrangements can be generated in a MC as a consequence of genome instability. As a co-effect, a poor-developed MC may be able to survive from a GECC and even be transformed by the GECC. Complex karyotypes are GECCs, and they are often seen in IAML cells. This may prove that IAML cells can survive from a GECC. Similarly, some MLL rearrangements and t(1;22) may be also GECCs, because they are mostly seen in IAMLs. Taken together, we hypothesize that IAML may develop as a consequence of defective development of HSCs/MCs by a genetic disorder.
JMML may develop also as a result of rapid cell transformation of a poor-developed MC. The cell of origin of JMML may be a granulocyte-monocyte progenitor (GMP). Some forms of abnormalities on chromosome 7, such as (+7) and (-7), may be the GECCs that are responsible for the "one-step" transformation of a GMP in JMML. The cell transformation in JMML may be at intermediate-grade, because the leukemia cells in JMML are relatively mature and they can enter bloodstream and infuse into organs.
XII. Summary
We have discussed in this paper the causing factors and the mechanism of cell transformation of a MC in development of myeloid leukemia. Here we give an outline of our work on studying AML and CML ( Figure 5 ). 
XIII. Conclusions
We have discussed in this paper the causes and the mechanism of transformation of a MC. We raise two hypotheses based on our discussion. Hypothesis A is: repeated bone-remodeling during bone-growth and bone-repair may be a source of cell injuries of marrow cells including HSCs, MCs, and LCs. Hypothesis B is: a MC may have two pathways on transformation: a slow and an accelerated. A transformation via slow pathway occurs at old age; whereas that via accelerated pathway occurs at any age. Therefore, CML and pediatric AML may develop as a result of transformation of a developing MC via accelerated pathway. To verify our hypothesis that bone-remodeling is related to the developments of AML and CML, experimental researches can be undertaken to study the association of repeated bone injuries with the incidence of myeloid leukemia in animal models (such as rabbits).
Occurrence of leukemia in a child is a tragedy. Our discussion can make us better understand this tragedy. Pediatric AML/CML may develop as a co-effect of three factors: A. higher survivability of a MC from DNA changes than a tissue cell; B. requiring obtaining fewer cancerous properties of a MC for cell transformation than a tissue cell, and C. higher risk of cell injuries of HSCs/ MCs in a child by repeated bone-remodeling for bone-growth. Thus, for reducing the risk of occurrence of AML/CML, avoiding violent sports and bone-injuries may be helpful. Cryopreservation of the HSCs in umbilical cord at birth is advised for the entire population.
